CAR T-Cell Therapy Shows Promise Against Relapsed Blood Cancers in Small Trial
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
20 articles
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
A phase 2 trial tests obinutuzumab, ibrutinib, and venetoclax in Richter's syndrome, a deadly CLL transformation with few treatment options.
French study explores how tiny cellular packages in blood could predict cancer recurrence and guide treatment decisions.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
Engineered immune cells target liver cancer protein in phase I safety study, though trial ended early with 10 patients.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.